Medication Summary
No specific agents are used to treat lizard envenomations. Although 2 experimental antivenoms have been produced for the Gila monster, neither has been made commercially available. Drug therapy is entirely symptomatic (eg, local anesthetics, analgesics, antiemetics). If antibiotics are administered, they should be broad-spectrum and they should provide coverage for gram-negative organisms. For the rare case of anaphylaxis/angioedema, therapy should be instituted with sympathomimetic agents, antihistamines, and/or steroids.
Cardiovascular Agents
Class Summary
Possess alpha- and beta-adrenergic effects that are useful in reversing anaphylactic reactions (eg, angioedema, bronchospasm, hypotension).
Epinephrine (Adrenalin, EpiPen)
DOC for the treatment of anaphylactoid reactions. Alpha-agonist effects increase peripheral vascular resistance and reverse peripheral vasodilatation and vascular permeability, thus helping to restore vascular tone and blood pressure. The beta-agonist effects increase heart rate and inotropism and cause bronchodilatation
Corticosteroids
Class Summary
Onset of action is approximately 4-6 h, although some synergistic activity may be noted when simultaneously used with sympathomimetic agents. Steroids may be needed in the rare event of an allergic reaction to lizard venom. Corticosteroids have no role in the management of envenomation itself.
Methylprednisolone (Solu-Medrol)
Decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability
Prednisone (Deltasone, Orasone, Meticorten)
Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Antihistamines
Class Summary
Prevent the histamine response in sensory nerve endings and blood vessels. More effective in preventing histamine response than in reversing it.
Diphenhydramine (Benadryl, Benylin, Bydramine)
Used for the symptomatic relief of allergic symptoms caused by histamine released in response to allergens.
Cimetidine (Tagamet)
An H2 antagonist that, when combined with an H1 type, may be useful in treating itching and flushing in anaphylaxis, pruritus, urticaria, and contact dermatitis that do not respond to H1-receptor antagonists alone. Use in addition to H1 antihistamines.
Local anesthetics
Class Summary
Local anesthetics can be injected, either locally or regionally, to aid in exploration of wounds (to rule out damage to underlying structures or retained teeth).
Lidocaine anesthetic
Amide local anesthetic used in 1-2% concentration. Inhibits depolarization of type C sensory neurons by blocking sodium channels. Epinephrine should be avoided in venomous lizard bites to prevent causing additional local tissue ischemia.
Analgesics
Class Summary
Patients may require narcotic analgesics for pain control after venomous lizard bites. In choosing a narcotic analgesic, to prevent worsening venom effects, it is best to select a narcotic that has less tendency to induce histamine release, such as fentanyl.
Fentanyl citrate (Sublimaze)
A synthetic opioid that is 75-200 times more potent and much shorter half-life than morphine sulfate. Has less hypotensive effects and is safer in patients with hyperactive airway disease than morphine because of minimal-to-no associated histamine release. By itself, it causes little cardiovascular compromise, although addition of benzodiazepines or other sedatives may result in decreased cardiac output and blood pressure.
Highly lipophilic and protein-bound. Prolonged exposure leads to accumulation in fat and delays weaning process.
Consider continuous infusion because of the short half-life of fentanyl. Parenteral form is DOC for conscious sedation analgesia. Ideal for analgesic action of short duration during anesthesia and immediate postoperative period.
Excellent choice for pain management and sedation with short duration (30-60 min) and easy to titrate. Easily and quickly reversed by naloxone.
After initial parenteral dose, subsequent parenteral doses should not be titrated more frequently than q3h or q6h thereafter.
Transdermal form is used only for chronic pain conditions in opioid-tolerant patients. When using transdermal dosage form, majority of patients are controlled with 72-h dosing intervals; however, some patients require dosing intervals of 48 h.
Easily and quickly reversed by naloxone.
Mebs D. Clinical toxicology of Helodermatidae lizard bites. In: Handbook of Clinical Toxicology of Animal Venoms and Poisons. 1995: 361-366.
Piacentine J, Curry SC, Ryan PJ. Life-threatening anaphylaxis following gila monster bite. Ann Emer Med. 1986;15:959-961. [Medline].
Bou-Abboud CF, Kardassakis DG. Acute myocardial infarction following a Gila monster (Heloderma suspectum cinctum) bite. West J Med. 1988;148(5):577-579. [Medline].
Preston CA. Hypotension, myocardial infarction, an coagulopathy following gila monster bite. J Emer Med. 1989;7:37-40. [Medline].
Brown DE, Carmony NB. Gila Monster: Facts and Folklore of America's Aztec Lizard. 1991;1-126.
Cantrell FL. Envenomation by the Mexican beaded lizard: a case report. J Toxicol Clin Toxicol. 2003;41(3):241-4. [Medline].
Hooker KR, Caravati EM. Gila monster envenomation. Ann Emerg Med. 1994;24(4):731-735. [Medline].
Kunkel DB. Bites of venomous reptiles. Emerg Med Clin North Am. Aug 1984;2(3):563-77. [Medline].
Kunkel DB, Curry SC, Vance MV, Ryan PJ. Reptile envenomations. J Toxicol Clin Toxicol. 1983-84;21(4-5):503-26. [Medline].
McNally J, Boesen K, Boyer L. Toxicologic information resources for reptile envenomations. Vet Clin North Am Exot Anim Pract. May 2008;11(2):389-401, viii. [Medline].
Miller MF. Gila monster envenomation. Ann Emerg Med. May 1995;25(5):720. [Medline].
Russell FE. Snake Venom Poisoning. Scholium International, Inc;1983:1-562.
Stahnke HL, Heffron WA, Lewis DL. Bite of the Gila monster. Rocky Mt Med J. Sep 1970;67(9):25-30. [Medline].
Streiffer RH. Bite of the venomous lizard, the Gila monster. Postgrad Med. Feb 1 1986;79(2):297-9, 302. [Medline].
Strimple PD, Tomassoni AJ, Otten EJ. Report on envenomation by a Gila monster (Heloderma suspectum) with a discussion of venom apparatus, clinical findings, and treatment. Wilderness Environ Med. May 1997;8(2):111-6. [Medline].

